Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | ALPL | P05186 | 1/20 | 0.54 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24313767 | 0.89 | TSHR (0.50) | ALDH1A1SMN1; SMN2TSHRKMT2AALPL | |
| SCHEMBL29469893 | 0.84 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2TSHRKMT2AALPL | |
| SCHEMBL31371876 | 0.84 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2TSHRKMT2AALPL | |
| SCHEMBL24314301 | 0.82 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2TSHRKMT2AALPL | |
| SCHEMBL10641518 | 0.82 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2TSHRTRPV4HPGD | |
| SCHEMBL24313728 | 0.81 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2TSHRKMT2AALPL | |
| SCHEMBL24313621 | 0.81 | GLRA1 (0.44) | ALDH1A1SMN1; SMN2TSHRKMT2AALPL | |
| SCHEMBL29469921 | 0.81 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2TSHRKMT2AALPL | |
| SCHEMBL2703971 | 0.79 | TSHR (0.62) | ALDH1A1SMN1; SMN2TSHRKMT2AALPL | |
| SCHEMBL34468880 | 0.79 | TSHR (0.58) | ALDH1A1SMN1; SMN2TSHRKMT2AALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138333-B2 | Sulfonyl-indole derivatives | PROXIMAGEN LIMITED (GB) | 2012-03-20 | — | — | US | disclosed |
| EP-2134714-A1 | TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY | Biovitrum AB (publ) (SE) | 2009-12-23 | — | — | EP | disclosed |
| US-20080293694-A1 | New compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-11-27 | — | — | US | disclosed |
| WO-2008110598-A1 | TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY | BIOVITRUM AB (PUBL) (SE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293694-A1 | New compounds | HTR6, HTR1A, HTR1B | ALDH1A1 901/4885SMN1; SMN2 1945/4885TSHR 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.